tiprankstipranks
TipRanksTop Financial ExpertsInsidersSrinivas Akkaraju

Srinivas Akkaraju Insider Profile

60 Followers
Srinivas Akkaraju, Director at Alumis Inc., holds 7.24M shares in Alumis Inc. (Ticker: ALMS), holds 6.93M shares in Scholar Rock Holding (Ticker: SRRK), holds 12.92M shares in Kalaris Therapeutics (Ticker: KLRS). Most recently, Srinivas Akkaraju Bought ― shares of Alumis Inc. on Sep 09, 2026 for an estimated value of $10.72M.
See the Hottest Stocks Based on Insider Trading >
tipranks
Srinivas Akkaraju

Srinivas Akkaraju
Alumis Inc. (ALMS)
Director

Ranked #6,295 out of 109,030 Corporate Insiders

Profitable Transactions

48%
19 out of 40 Profitable Transactions

Average Return

+12.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
How are Insiders Ranked?

Insider Holdings

$670M
57.31%
24.75%
9.92%
6.52%
1.49% Others
A breakdown of Srinivas Akkaraju's holdings
See the Top Stocks by Insiders

Insider Roles

Scholar Rock Holding
(SRRK)
Director
Mineralys Therapeutics, Inc.
(MLYS)
Director, Ten Percent Owner
Alumis Inc.
(ALMS)
Director
Kalaris Therapeutics
(KLRS)
Director
+2 other positions
Roles that Srinivas Akkaraju holds in companies
See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:
Alumis Inc.
(ALMS)
Rating:Informative Buy
Date:May 06, 2025 - May 06, 2026
Return:+486.20%
The most profitable trade made by Srinivas Akkaraju
See the Latest Stocks Traded by Insiders

Srinivas Akkaraju's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
ALMS
Alumis Inc.
Sep 09, 2026
Director
Informative Buy
10.72M
$66.46M
KLRS
Kalaris Therapeutics
May 22, 2026
Director
Informative Buy
1.18M
$43.65M
ZSPH
ZS Pharma
Dec 21, 2015
―
Uninformative Sell
90.00K
$0.00
SYRS
Syros Pharmaceuticals
Sep 18, 2024
Director
Uninformative Buy
5.28K
―
PRNB
Principia Biopharma
Sep 20, 2018
―
Uninformative Buy
―
$38.37M
KDNY
Chinook Therapeutics
Aug 11, 2023
―
Uninformative Sell
―
$0.00
JYAC
Jiya Acquisition
―
―
―
―
SRRK
Scholar Rock Holding
Jun 08, 2026
Director
Uninformative Buy
―
$383.75M
MLYS
Mineralys Therapeutics, Inc.
Feb 20, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$165.74M
VTVT
vTv Therapeutics
Sep 25, 2025
Director
Uninformative Buy
1.62M
$10.00M
ARAV
Aravive
Dec 02, 2019
―
Informative Buy
1000.00K
$24.32K
ICPT
Intercept Pharma
May 25, 2023
―
Uninformative Buy
―
$13.05M
SGEN
Seagen
May 19, 2020
―
Uninformative Buy
―
$9.49M
GEVA
Synageva
Jun 28, 2012
―
Informative Sell
13.60M
―
List of latest transactions for each holding click on a transaction to see Srinivas Akkaraju's performance on stock
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Srinivas Akkaraju insider profile FAQ

What is the percentage of profitable transactions made by Srinivas Akkaraju?
The percentage of profitable transactions made by Srinivas Akkaraju is 48%.
    What is the average return per transaction made by Srinivas Akkaraju?
    The average return per transaction made by Srinivas Akkaraju is 12.80%.
      What stocks does Srinivas Akkaraju hold?
      Srinivas Akkaraju holds: ALMS, KLRS, ZSPH, SYRS, PRNB, KDNY, JYAC, SRRK, MLYS, VTVT, ARAV, ICPT, SGEN, GEVA stocks.
        What was Srinivas Akkaraju’s latest transaction?
        Srinivas Akkaraju latest transaction was an Informative Buy of $10.72M.
          What was Srinivas Akkaraju's most profitable transaction?
          Srinivas Akkaraju’s most profitable transaction was an Informative Buy of ALMS stock on May 6, 2025. The return on the trade was 486.20%.
            What is Srinivas Akkaraju's role in Alumis Inc.?
            Srinivas Akkaraju's role in Alumis Inc. is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.